Complete Filing Data
Basel Medical Group Ltd reported Cash And Cash Equivalents of $2.98 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Basel Medical Group Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Profit Loss Including Minority Interest | -$12.1M | $2.1M |
| Profit Loss Before Tax | -$12.5M | $2.4M |
| Profit Loss Attributable To Owners Of Parent | -$12.1M | $2.1M |
| Profit Loss And Net Comprehensive Income | -$12.1M | $2.1M |
| Profit Loss | -$12.1M | $2.1M |
| Merger Reserve Arising From Group Restructuring | $24.5M | $24.5M |
| Income Taxes Paid Refund Classified As Operating Activities | $648.3K | $176.2K |
| Income Tax Expense Continuing Operations | -$417.4K | $331.8K |
| Adjustments For Interest Expense | $203.9K | $176.2K |
| Profit Loss Attributable To Noncontrolling Interests | -$501.00 | |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$465.9K | |
| Other Comprehensive Income Before Tax | -$12.1M | |
| Impairment Loss | $11.1M | |
| Adjustments For Impairment Loss Recognised In Profit Or Loss Goodwill | $11.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash And Cash Equivalents | $3.0M | $2.0M | $1.2M |
| Trade And Other Current Receivables | $9.7M | $2.0M | |
| Trade And Other Current Payables | $6.9M | $2.6M | |
| Rightofuse Assets | $3.2M | $23.5K | |
| Retained Earnings | -$4.4M | $7.6M | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $54.8K | $7.9K | |
| Property Plant And Equipment | $277.5K | $34.5K | |
| Other Current Financial Liabilities | $1.6M | $1.3M | |
| Noncurrent Assets | $3.7M | $135.0K | |
| Net Assets Liabilities | $4.9M | $7.6M | |
| Liabilities | $12.0M | $8.7M | |
| Issue Of Equity | $9.8M | $24.5M | |
| Deferred Tax Assets | $282.0K | $77.0K | |
| Deferred Offering Cost | $31.8K | $1.6M | |
| Current Assets | $13.1M | $16.2M | |
| Cash Flows From Used In Operations Before Changes In Working Capital | -$240.4K | $3.1M | |
| Cash Flows From Used In Operations | -$3.5M | $3.1M | |
| Cash Flows From Used In Operating Activities | -$4.3M | $2.5M | |
| Cash Flows From Used In Investing Activities | -$11.0M | -$7.9K | |
| Cash Flows From Used In Financing Activities | $16.9M | -$1.8M | |
| Cash Advances And Loans From Related Parties | $10.6M | -$73.00 | |
| Assets | $16.9M | $16.3M | |
| Adjustments For Increase Decrease In Trade Account Payable | -$4.3M | -$387.7K | |
| Adjustments For Decrease Increase In Trade Account Receivable | -$7.3M | -$415.1K | |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | $11.0M | ||
| Recoveries On Loans Previously Written Off Fixed Assets | $176.2K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Proceeds From Issue Of Ordinary Shares | 9.8M | 18.4M | |
| Proceeds From Deferred Offering Costs | -$1.6M | $1.6M | |
| Payments Of Lease Liabilities Classified As Financing Activities | $981.3K | $566.0K | |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $1.5M | $733.6K | |
| Proceeds From Current Borrowings | $4.0M | ||
| Proceeds From Contributions Of Noncontrolling Interests | $3.5K | ||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$495.7K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Diluted Earnings Loss Per Share | $-0.64 | $0.13 |
| Basic Earnings Loss Per Share | $-0.64 | $0.13 |
| Weighted Average Shares | 18.8M | 16.3M |
| Adjusted Weighted Average Shares | 18.8M | 16.3M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Shortterm Borrowings | $2.1M | $2.7M |
| Repayments Of Borrowings Classified As Financing Activities | $8.3M | $2.4M |
| Rental Expense | $141.1K | $3.2K |
| Other Operating Income Expense | -$3.3M | -$1.5M |
| Other Gains Losses | $1.1M | $461.0K |
| Longterm Borrowings | $1.3M | $1.6M |
| Issued Capital | $34.2M | $24.5M |
| Inventories | $376.3K | $72.0K |
| Interest Paid Classified As Operating Activities | $203.9K | $413.6K |
| Increase In Amount Due To Related Parties | -$331.2K | -$1.3M |
| Finance Costs | $203.9K | $176.2K |
| Employee Benefits Expense | $6.4M | $3.6M |
| Depreciation Expense | $1.2M | $528.7K |
| Decreaseincrease In Amount Due To Former Director | $111.5K | -$111.5K |
| Current Provisions For Employee Benefits | $15.0K | $15.0K |
| Consumables Medical Supplies And Other Related Expenses | $2.5M | $2.2M |
| Adjustments For Provisions | -$682.3K | $50.2K |
| Adjustments For Depreciation Expense | $107.7K | $30.1K |
| Adjustments For Decrease Increase In Inventories | -$304.3K | $22.6K |
| Adjustments For Amortization Of Right Of Use Asset | $1.1M | $498.6K |
| Recoveries On Loans Previously Written Off | $240.4K | |
| Other Reserves | -$495.7K | |
| Noncontrolling Interests | $3.5K | |
| Increase Decrease Through Sharebased Payment Transactions | $100.0K | |
| Purchase Of Investment Property | $49.00 |
Most recent annual filing with the SEC: November 18, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.